英科醫療(300677.SZ)一季度預盈36億-38億元 同比增長2686.6%-2841.41%
格隆匯 4 月 14日丨英科醫療(300677.SZ)公佈,預計2021年第一季度歸屬於上市公司股東的淨利潤36億元-38億元,同比增長2686.60%-2841.41%;扣除非經常性損益後的淨利潤35.93億元-37.93億元,同比增長2773.08%-2933%。業績變動原因如下:
(1)報吿期內新型冠狀病毒疫情仍在持續,國內外一次性防護手套需求依舊旺盛,對公司業績產生了積極影響;
(2)報吿期內公司安徽生產基地有新增丁腈生產線投產,使得公司報吿期內銷售收入和毛利均有提升;同時公司通過內部的不斷精益、改善和創新,進一步降低了能耗,提高了生產效率;
(3)報吿期內手套的多種原材料價格仍在高位和美元匯率處於低位,對公司業績有一定抑制作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.